Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07033585 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

Study acronym: GD-T2D
StatusActive, Not Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Sponsor changed: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair to Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair Start date: Jun 15, 2025 to Jun 15, 2026v3 Show 1 more changeShow less
    • Start date: Jun 15, 2025 to Jun 15, 2026

    See this version in full on ClinicalTrials.gov ↗

  2. Eligibility criteria shortened, about 4 wordsv2 See this version in full on ClinicalTrials.gov ↗
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Use Dapagliflozin 10 mg, Saxagliptin 5 mg, Metformin 500 mg treat type 2 diabetes patients with controlled cancers
Trial Details
NCT Number NCT07033585
Lead Sponsor Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
Collaborators: UnitedHealthcare
Conditions Type 2 Diabetes
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov